# DESCRIPTION

- introduce cancer treatment
- limitations of conventional cancer therapies
- motivate selective delivery of therapeutic agents
- describe tenascin-C and its role in tumourigenesis
- summarize monoclonal antibodies specific to tenascin-C
- describe delivery of bioactive agents to tumour tissue
- introduce L19 and F16 antibodies
- describe clinical development of immunocytokines
- motivate treatment of central nervous system tumours
- describe standard of care for glioblastoma
- introduce inventors' observation of synergistic effect
- describe aspects of the first development of the invention
- describe aspects of the second development of the invention
- describe aspects of the third development of the invention

## DETAILED DESCRIPTION

- define chemotherapeutic agents
- describe alkylating agents
- introduce temozolomide
- describe tumours that may be treated
- introduce antibody moiety
- describe immunocytokine formats

### VL CDR3 SEQ ID NO: 10

- describe antibody 4A1-F16
- introduce VH and VL domain sequences
- describe VH CDR1 sequences
- describe VL CDR1 sequences
- describe suitable antibody formats
- introduce scFv antibody molecule
- describe SIP comprising homodimer of scFv
- describe CH4 domain
- introduce IL2 conjugated to antibody molecule
- describe IL2 sequence
- introduce mature human IL2 sequence
- describe IL2 variants
- describe IL2 fusion to antibody molecule
- introduce peptide linker
- describe preferred linker sequence

## TERMINOLOGY

### Antibody Molecule

- define antibody molecule
- describe antibody fragments
- motivate chimeric molecules
- introduce human or humanised antibody molecules
- describe binding fragments
- motivate antibody fragments by genetic recombination
- describe functional antibody fragments
- introduce dAb and Nanobodies
- describe bispecific or bifunctional antibodies
- motivate methods for obtaining antibodies

### Antigen-Binding Site

- define antigen-binding site
- describe engineering of antigen binding sites

## EXPERIMENTS

### Summary

- describe therapeutic properties of temozolomide in combination with F16-IL2

### Immunohistochemistry on Human Glioblastoma Samples and on Glioblastoma Xenografts

- describe immunohistochemical procedures
- evaluate expression of A1 domain of tenascin-C and EDB domain of fibronectin

### Cell Lines and Animals

- describe cell lines and animals used

### Antibodies and Therapeutic Agents

- describe antibodies and therapeutic agents used

### Biodistribution Experiments

- evaluate in vivo targeting performance of F16-IL2

### Subcutaneous Glioma Mouse Models

- describe subcutaneous glioblastoma bearing mice model
- evaluate therapeutic efficacy of F16-IL2 and temozolomide

### Immunofluorescence Assessment of Tumour-Infiltrating Cells and of Microvascular Density in Subcutaneous Glioma Xenografts

- evaluate role of inflammatory cell responses in vivo
- assess microvascular density in subcutaneous glioma xenografts

### Statistical Analysis

- describe biodistribution data analysis
- describe tumour volume analysis
- describe Kaplan-Meier survival curve analysis
- describe statistical analysis of immunofluorescence data

